Akademik Veri Yönetim Sistemi
Journal of B.U.ON., cilt.26, sa.6, ss.2496-2504, 2021 (SCI-Expanded)
Purpose: There are many studies about the administration of gemcitabine and 5-fluorouracil combination regimen for advanced-stage pancreatic ductal adenocarcinoma (PDAC), but no study exists about early-stage PDAC. This study, for the first time, aimed to evaluate the efficacy and tolerability of gemcitabine and infusional 5-fluorouracil with high-dose folinic acid as adjuvant chemotherapy after curative surgery for PDAC. Methods: Patients with curatively resected PDAC were treated with gemcitabine combined with infusional 5-fluorouracil and high-dose folinic acid (GEMFUFOL). This combination regimen was repeated every 2 weeks. Results: A total of 62 patients who received GEMFUFOL as adjuvant chemotherapy were included in this study. At a median follow-up of 16.9 months (range, 3.6-149.2), median disease-free survival (DFS) was 11.8 months (95% CI, 7.9- 15.6), with 1-year, 2-year and 3-year DFS rates of 49%, 15% and 11% identified. Median overall survival (OS) was 17.3 months (95% CI, 12.4-22.1) with 1-year, 2-year and 3-year OS rates of 72%, 37% and 17%. Severe toxicity was rarely observed. Two patients (3.2%) developed grade 4 neutropenia; however, febrile neutropenia was observed in 1 patient (1.6%). Three patients (4.8%) had grade 3 neutropenia, 2 patients (3.2%) had grade 3 anemia, 3 patients (4.8%) had grade 3 nausea, 1 patient (1.6%) had grade 3 diarrhea and 1 patient (1.6%) had grade 3 infection. Conclusions: The GEMFUFOL regimen is an effective and tolerable regimen for adjuvant treatment of PDAC and may be an appropriate alternative for patients unsuitable for current standard treatments.